Macrophages are crucial orchestrators of host defence and tissue homeostasis. Macrophages are heterogeneous and plastic cells that in response to different microenvironmental signals can mount a broad spectrum of different programs of polarized activation. In different pathological contexts including cancer and infectious diseases, macrophages diversity and plasticity may act as a double-edged sword. The elucidation of the molecular mechanisms underlying macrophages recruitment and functional activation allows the identification of valuable targets for the development of innovative therapeutic approaches.

Keywords:

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

1 Gordon S. Elie Metchnikoff: father of natural immunity. Eur. J. Immunol.38(12),3257–3264 (2008).
Medline CASGoogle Scholar
2 Podolsky SH, Tauber AI. Darwinism and antibody diversity: a historical perspective. Res. Immunol.147(4),199–202 (1996).
Medline CASGoogle Scholar
3 Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol.8(12),958–969 (2008).
Medline CASGoogle Scholar
4 Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol.27,451–483 (2009).
Medline CASGoogle Scholar
5 Pollard JW. Trophic macrophages in development and disease. Nat. Rev. Immunol.9(4),259–270 (2009).
Medline CASGoogle Scholar
6 Stout RD, Watkins SK, Suttles J. Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages. J. Leukoc. Biol.86(5),1105–1109 (2009).
Medline CASGoogle Scholar
7 Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol.11(10),889–896 (2010).▪ Emphasizes macrophage plasticity by discussing the bidirectional interaction between macrophages and lymphocytes in cancer.
Medline CASGoogle Scholar
8 Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science327(5966),656–661 (2010).▪ Highlights that circulating monocytes consist of two subsets with distinct phenotypical and functional features.
Medline CASGoogle Scholar
9 Yona S, Jung S. Monocytes: subsets, origins, fates and functions. Curr. Opin Hematol.17(1),53–59 (2010).
MedlineGoogle Scholar
10 Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity19(1),71–82 (2003).
Medline CASGoogle Scholar
11 Pucci F, Venneri MA, Biziato D et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood ‘resident’ monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood114(4),901–914 (2009).▪ Tie2-expressing monocytes (TEMs) are profiled by microarray analysis. The authors suggest TEMs as a new subset of proangiogenic monocytes committed to development angiogenesis and co-opted by tumors.
Medline CASGoogle Scholar
12 Coffelt SB, Tal AO, Scholz A et al. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res.70(13),5270–5280 (2010).
Medline CASGoogle Scholar
13 Robbins CS, Swirski FK. The multiple roles of monocyte subsets in steady state and inflammation. Cell Mol. Life Sci.67(16),2685–93 (2010).
Medline CASGoogle Scholar
14 Le Borgne M, Etchart N, Goubier A et al. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8⁺ T cell crosspriming in vivo. Immunity24(2),191–201 (2006).
Medline CASGoogle Scholar
15 Combadiere C, Potteaux S, Rodero M et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C^(hi) and Ly6C^(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation117(13),1649–1657 (2008).
Medline CASGoogle Scholar
16 Auffray C, Fogg D, Garfa M et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science317(5838),666–670 (2007).
Medline CASGoogle Scholar
17 Jakubzick C, Tacke F, Ginhoux F et al. Blood monocyte subsets differentially give rise to CD103⁺ and CD103^- pulmonary dendritic cell populations. J. Immunol.180(5),3019–3027 (2008).
Medline CASGoogle Scholar
18 De Palma M, Murdoch C, Venneri MA, Naldini L, Lewis CE. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol.28(12),519–524 (2007).
Medline CASGoogle Scholar
19 Welford AF, Biziato D, Coffelt SB et al. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J. Clin. Invest.121(5),1969–1973 (2011).▪▪ Demonstrates that CXCL12/CXCR4 axis drives TEMs recruitment in tumors thereby imparing the therapeutic efficacy of antiangiogenic drugs.
Medline CASGoogle Scholar
20 De Palma M, Venneri MA, Galli R et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell8(3),211–226 (2005).▪ Identifies TEMs as a new subset of tumor associated monocytes with strong proangiogenic activity.
Medline CASGoogle Scholar
21 Murdoch C, Tazzyman S, Webster S, Lewis CE. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J. Immunol.178(11),7405–7411 (2007).
Medline CASGoogle Scholar
22 Venneri MA, De Palma M, Ponzoni M et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood109(12),5276–5285 (2007).
Medline CASGoogle Scholar
23 Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol.23(11),549–555 (2002).▪ The first review on macrophages plasticity suggesting M1 and M2 as the extremes of a continuum of different states of polarized activation.
Medline CASGoogle Scholar
24 Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol.5(12),953–964 (2005).
Medline CASGoogle Scholar
25 Gratchev A, Schledzewski K, Guillot P, Goerdt S. Alternatively activated antigen-presenting cells: molecular repertoire, immune regulation, and healing. Skin Pharmacol. Appl. Skin Physiol.14(5),272–279 (2001).
Medline CASGoogle Scholar
26 Bystrom J, Evans I, Newson J et al. Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood112(10),4117–4127 (2008).
Medline CASGoogle Scholar
27 Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Curr. Opin Rheumatol.19(3),289–295 (2007).
MedlineGoogle Scholar
28 Zhang X, Mosser DM. Macrophage activation by endogenous danger signals. J. Pathol.214(2),161–178 (2008).
Medline CASGoogle Scholar
29 Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell140(6),883–899 (2010).
Medline CASGoogle Scholar
30 Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest.117(1),175–184 (2007).
Medline CASGoogle Scholar
31 Zeyda M, Stulnig TM. Adipose tissue macrophages. Immunol. Lett.112(2),61–67 (2007).
Medline CASGoogle Scholar
32 Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity32(5),593–604 (2010).
Medline CASGoogle Scholar
33 Mantovani A. Cancer: inflaming metastasis. Nature457(7225),36–37 (2009).
Medline CASGoogle Scholar
34 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell144(5),646–674 (2011).
Medline CASGoogle Scholar
35 Vannucci L, Stepankova R, Grobarova V et al. Colorectal carcinoma: Importance of colonic environment for anti-cancer response and systemic immunity. J. Immunotoxicol.6(4),217–226 (2009).
MedlineGoogle Scholar
36 Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature454(7203),436–444 (2008).▪ Examines the molecular mechanisms linking inflammation with cancer.
Medline CASGoogle Scholar
37 Porta C, Riboldi E, Sica A. Mechanisms linking pathogens-associated inflammation and cancer. Cancer Lett.305(2),250–262 (2011).
Medline CASGoogle Scholar
38 Bingle L, Brown NJ, Lewis CE. The role of tumor-associated macrophages in tumor progression: implications for new anticancer therapies. J. Pathol.196(3),254–265 (2002).
Medline CASGoogle Scholar
39 Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell141(1),39–51 (2010).
Medline CASGoogle Scholar
40 Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest.117(5),1155–1166 (2007).
Medline CASGoogle Scholar
41 Bottazzi B, Polentarutti N, Acero R et al. Regulation of the macrophage content of neoplasms by chemoattractants. Science220(4593),210–212 (1983).
Medline CASGoogle Scholar
42 Bottazzi B, Walter S, Govoni D, Colotta F, Mantovani A. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J. Immunol.148(4),1280–1285 (1992).
Medline CASGoogle Scholar
43 Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin Immunol.22(2),231–237 (2010).
Medline CASGoogle Scholar
44 Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev.21(1),27–39 (2010).
Medline CASGoogle Scholar
45 Zhang J, Sud S, Mizutani K, Gyetko MR, Pienta KJ. Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia13(1),23–30 (2011).
MedlineGoogle Scholar
46 Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat. Rev. Cancer9(4),239–252 (2009).
Medline CASGoogle Scholar
47 Byrne SN, Knox MC, Halliday GM. TGFβ is responsible for skin tumor infiltration by macrophages enabling the tumors to escape immune destruction. Immunol. Cell Biol.86(1),92–97 (2008).
Medline CASGoogle Scholar
48 Jin G, Kawsar HI, Hirsch SA et al. An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis. PLoS ONE5(6),e10993 (2010).▪ Demonstrates β-defensin-3 as a new monocyte chemoattractant in gastric cancer.
MedlineGoogle Scholar
49 Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell7(3),211–217 (2005).
Medline CASGoogle Scholar
50 Pikarsky E, Porat RM, Stein I et al. NF-κB functions as a tumor promoter in inflammation-associated cancer. Nature431(7007),461–466 (2004).
Medline CASGoogle Scholar
51 Greten FR, Karin M. The IKK/NF-κB activation pathway-a target for prevention and treatment of cancer. Cancer Lett.206(2),193–199 (2004).
Medline CASGoogle Scholar
52 Hagemann T, Wilson J, Burke F et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J. Immunol.176(8),5023–5032 (2006).
Medline CASGoogle Scholar
53 Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-κB-dependent manner. Cancer Cell17(2),135–147 (2010).
Medline CASGoogle Scholar
54 Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE4(11),e7965 (2009).
MedlineGoogle Scholar
55 Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol.179(2),977–983 (2007).
Medline CASGoogle Scholar
56 De Nardo DG, Barreto JB, Andreu P et al. CD4(⁺) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell16(2),91–102 (2009).
Medline CASGoogle Scholar
57 Andreu P, Johansson M, Affara NI et al. FcRγ activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell17(2),121–134 (2010).
Medline CASGoogle Scholar
58 De Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell7(5),411–423 (2005).
Medline CASGoogle Scholar
59 Wong SC, Puaux AL, Chittezhath M et al. Macrophage polarization to a unique phenotype driven by B cells. Eur. J. Immunol.40(8),2296–2307 (2010).
Medline CASGoogle Scholar
60 Dinapoli MR, Calderon CL, Lopez DM. The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene. J. Exp. Med.183(4),1323–1329 (1996).
Medline CASGoogle Scholar
61 Sica A, Saccani A, Bottazzi B et al. Autocrine production of IL-10 mediates defective IL-12 production and NF-κ B activation in tumor-associated macrophages. J. Immunol.164(2),762–767 (2000).
Medline CASGoogle Scholar
62 Saccani A, Schioppa T, Porta C et al. p50 nuclear factor-κB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res.66(23),11432–11440 (2006).
Medline CASGoogle Scholar
63 Ojalvo LS, King W, Cox D, Pollard JW. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am. J. Pathol.174(3),1048–1064 (2009).
Medline CASGoogle Scholar
64 Budhu A, Forgues M, Ye QH et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell10(2),99–111 (2006).
Medline CASGoogle Scholar
65 Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science313(5795),1960–1964 (2006).
Medline CASGoogle Scholar
66 Kurahara H, Shinchi H, Mataki Y et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J. Surg. Res.167(2),E211–E219 (2009).
MedlineGoogle Scholar
67 Steidl C, Lee T, Shah SP et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N. Engl. J. Med.362(10),875–885 (2010).▪ Demonstrates that tumor-associated macrophages have prognostic sugnificance in Hodgkin’s disease and calls for using tumor-associated macrophages in Hodgkin’s disease classification and treatment.
Medline CASGoogle Scholar
68 Duluc D, Delneste Y, Tan F et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood110(13),4319–4330 (2007).
Medline CASGoogle Scholar
69 Roca H, Varsos Z, Pienta KJ. CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin upregulation. J. Biol. Chem.283(36),25057–25073 (2008).
Medline CASGoogle Scholar
70 Fridlender ZG, Kapoor V, Buchlis G et al. Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8⁺ cells. Am. J. Respir. Cell Mol. Biol.44(2),230–237 (2011).
Medline CASGoogle Scholar
71 Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol.8(7),533–544 (2008).
Medline CASGoogle Scholar
72 Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol.177(10),7303–7311 (2006).
Medline CASGoogle Scholar
73 Solinas G, Schiarea S, Liguori M et al. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J. Immunol.185(1),642–652 (2010).
Medline CASGoogle Scholar
74 Banerjee S, Lin CF, Skinner KA et al. Heat shock protein 27 differentiates tolerogenic macrophages that may support human breast cancer progression. Cancer Res.71(2),318–327 (2011).
Medline CASGoogle Scholar
75 Lepique AP, Daghastanli KR, Cuccovia IM, Villa LL. HPV16 tumor-associated macrophages suppress antitumor T cell responses. Clin. Cancer Res.15(13),4391–4400 (2009).
Medline CASGoogle Scholar
76 Coffelt SB, Chen YY, Muthana M et al. Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. J. Immunol.186(7),4183–4190 (2011).
Medline CASGoogle Scholar
77 Gallina G, Dolcetti L, Serafini P et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8⁺ T cells. J. Clin. Invest.116(10),2777–2790 (2006).
Medline CASGoogle Scholar
78 Lindenberg JJ, Fehres CM, Van Cruijsen H, Oosterhoff D, De Gruijl TD. Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity. Immunotherapy3(1),77–96 (2011).
CASGoogle Scholar
79 Lin EY, Li JF, Gnatovskiy L et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res.66(23),11238–11246 (2006).
Medline CASGoogle Scholar
80 Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res.56(20),4625–4629 (1996).
Medline CASGoogle Scholar
81 Nishie A, Ono M, Shono T et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin. Cancer Res.5(5),1107–1113 (1999).
Medline CASGoogle Scholar
82 Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y. Prognostic value of tumor-associated macrophage count in human bladder cancer. Int. J. Urol.7(7),263–269 (2000).
Medline CASGoogle Scholar
83 Koide N, Nishio A, Sato T, Sugiyama A, Miyagawa S. Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. Am. J. Gastroenterol.99(9),1667–1674 (2004).
Medline CASGoogle Scholar
84 Toge H, Inagaki T, Kojimoto Y, Shinka T, Hara I. Angiogenesis in renal cell carcinoma: the role of tumor-associated macrophages. Int. J. Urol.16(10),801–807 (2009).
Medline CASGoogle Scholar
85 De Palma M, Venneri MA, Roca C, Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med.9(6),789–795 (2003).
Medline CASGoogle Scholar
86 Fantin A, Vieira JM, Gestri G et al. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood116(5),829–840 (2010).▪▪ TEMs have a crucial role in development angiogenesis by promoting vascular anastomosis.
Medline CASGoogle Scholar
87 Rolny C, Mazzone M, Tugues S et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell19(1),31–44 (2011).▪▪ Provocative study showing that tumor-associated macrophages support the construction of an abnormal vasculature.
Medline CASGoogle Scholar
88 Wyckoff JB, Wang Y, Lin EY et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res.67(6),2649–2656 (2007).
Medline CASGoogle Scholar
89 Robinson BD, Sica GL, Liu YF et al. Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin. Cancer Res.15(7),2433–2441 (2009).
Medline CASGoogle Scholar
90 Qian B, Deng Y, Im JH et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE4(8),e6562 (2009).
MedlineGoogle Scholar
91 Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol.8(12),1369–1375 (2006).
Medline CASGoogle Scholar
92 Hiratsuka S, Watanabe A, Sakurai Y et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell Biol.10(11),1349–1355 (2008).▪▪ Highlights the S100A8/S100A9- serum amyloid A3-TLR4 as a crucial circuit underlying macrophages activation and premetastic niches creation.
Medline CASGoogle Scholar
93 Said N, Smith S, Sanchez-Carbayo M, Theodorescu D. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J. Clin. Invest.121(1),132–147 (2011).▪▪ Demonstrates that early recruitment of macrophages in the lungs by the endothelin-1/endothelin-1 receptor axis is an essential event for metastatic lung colonization.
Medline CASGoogle Scholar
94 Kaufmann SH. Robert Koch, the Nobel Prize, and the ongoing threat of tuberculosis. N. Engl. J. Med.353(23),2423–6 (2005).
Medline CASGoogle Scholar
95 Cooper AM. Cell-mediated immune responses in tuberculosis. Annu. Rev. Immunol.27,393–422 (2009).
Medline CASGoogle Scholar
96 Harding CV, Boom WH. Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors. Nat. Rev. Microbiol.8(4),296–307 (2010).
Medline CASGoogle Scholar
97 Flannagan RS, Cosio G, Grinstein S. Antimicrobial mechanisms of phagocytes and bacterial evasion strategies. Nat. Rev. Microbiol.7(5),355–366 (2009).
Medline CASGoogle Scholar
98 Liu PT, Modlin RL. Human macrophage host defense against Mycobacterium tuberculosis. Curr. Opin Immunol.20(4),371–376 (2008).
Medline CASGoogle Scholar
99 Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat. Immunol.10(9),943–948 (2009).
Medline CASGoogle Scholar
100 Liu PT, Stenger S, Li H et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science311(5768),1770–1173 (2006).
Medline CASGoogle Scholar
101 Yadav M, Schorey JS. The β-glucan receptor dectin-1 functions together with TLR2 to mediate macrophage activation by mycobacteria. Blood108(9),3168–3175 (2006).
Medline CASGoogle Scholar
102 Benoit M, Desnues B, Mege JL. Macrophage polarization in bacterial infections. J. Immunol.181(6),3733–3739 (2008).
Medline CASGoogle Scholar
103 Flynn JL, Chan J, Triebold KJ et al. An essential role for interferon γ in resistance to Mycobacterium tuberculosis infection. J. Exp. Med.178(6),2249–5224 (1993).▪▪ Demonstrates the essential role of IFN-γ in resistance to Mycobacterium tuberculosis infection.
Medline CASGoogle Scholar
104 Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG, Mycobacterium tuberculosis survival in infected macrophages. Cell119(6),753–766 (2004).
Medline CASGoogle Scholar
105 Delgado MA, Elmaoued RA, Davis AS, Kyei G, Deretic V. Toll-like receptors control autophagy. EMBO J.27(7),1110–2111 (2008).
Medline CASGoogle Scholar
106 Russell DG. Mycobacterium tuberculosis and the intimate discourse of a chronic infection. Immunol. Rev.240(1),252–268 (2011).
Medline CASGoogle Scholar
107 Pathak SK, Basu S, Basu KK et al. Direct extracellular interaction between the early secreted antigen ESAT-6 of Mycobacterium tuberculosis and TLR2 inhibits TLR signaling in macrophages. Nat. Immunol.8(6),610–618 (2007).
Medline CASGoogle Scholar
108 Ting LM, Kim AC, Cattamanchi A, Ernst JD. Mycobacterium tuberculosis inhibits IFN-γ transcriptional responses without inhibiting activation of STAT1. J. Immunol.163(7),3898–3906 (1999).
Medline CASGoogle Scholar
109 Nagabhushanam V, Solache A, Ting LM, Escaron CJ, Zhang JY, Ernst JD. Innate inhibition of adaptive immunity: Mycobacterium tuberculosis-induced IL-6 inhibits macrophage responses to IFN-γ. J. Immunol.171(9),4750–4757 (2003).
Medline CASGoogle Scholar
110 Rajaram MV, Brooks MN, Morris JD, Torrelles JB, Azad AK, Schlesinger LS. Mycobacterium tuberculosis activates human macrophage peroxisome proliferator-activated receptor γ linking mannose receptor recognition to regulation of immune responses. J. Immunol.185(2),929–942 (2010).
Medline CASGoogle Scholar
111 Schreiber T, Ehlers S, Heitmann L et al. Autocrine IL-10 induces hallmarks of alternative activation in macrophages and suppresses antituberculosis effector mechanisms without compromising T cell immunity. J. Immunol.183(2),1301–1312 (2009).
Medline CASGoogle Scholar
112 Harris J, De Haro SA, Master SS et al. T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. Immunity27(3),505–517 (2007).
Medline CASGoogle Scholar
113 Pieters J. Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe3(6),399–407 (2008).
Medline CASGoogle Scholar
114 Peters W, Ernst JD. Mechanisms of cell recruitment in the immune response to Mycobacterium tuberculosis. Microbes Infect.5(2),151–158 (2003).
Medline CASGoogle Scholar
115 Algood HM, Chan J, Flynn JL. Chemokines and tuberculosis. Cytokine Growth Factor Rev.14(6),467–477 (2003).▪ Describes chemokine involvement in the immune response against M. tuberculosis.
Medline CASGoogle Scholar
116 Peters W, Scott HM, Chambers HF, Flynn JL, Charo IF, Ernst JD. Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA98(14),7958–7963 (2001).▪▪ Demonstrates the requirement for CCR2 in the initial immune reponse and control of infection with M. tuberculosis.
Medline CASGoogle Scholar
117 Lu B, Rutledge BJ, Gu L et al. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J. Exp. Med.187(4),601–608 (1998).
Medline CASGoogle Scholar
118 Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol.168(9),4620–4627 (2002).
Medline CASGoogle Scholar
119 Flynn JL, Goldstein MM, Chan J et al. Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity2(6),561–572 (1995).
Medline CASGoogle Scholar
120 Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med.345(15),1098–1104 (2001).
Medline CASGoogle Scholar
121 Leemans JC, Florquin S, Heikens M, Pals ST, van Der Neut R, Van Der Poll T. CD44 is a macrophage binding site for Mycobacterium tuberculosis that mediates macrophage recruitment and protective immunity against tuberculosis. J. Clin. Invest.111(5),681–689 (2003).
Medline CASGoogle Scholar
122 Taylor JL, Hattle JM, Dreitz SA et al. Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Infect. Immun.74(11),6135–6144 (2006).
Medline CASGoogle Scholar
123 Carter CA, Ehrlich LS. Cell biology of HIV-1 infection of macrophages. Annu. Rev. Microbiol.62,425–443 (2008).
Medline CASGoogle Scholar
124 Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol.17,657–700 (1999).
Medline CASGoogle Scholar
125 Herbein G, Varin A. The macrophage in HIV-1 infection: from activation to deactivation? Retrovirology7,33 (2010).
MedlineGoogle Scholar
126 Wahl SM, Greenwell-Wild T, Hale-Donze H, Moutsopoulos N, Orenstein JM. Permissive factors for HIV-1 infection of macrophages. J. Leukoc. Biol.68(3),303–310 (2000).
Medline CASGoogle Scholar
127 Orenstein JM, Fox C, Wahl SM. Macrophages as a source of HIV during opportunistic infections. Science276(5320),1857–1861 (1997).
Medline CASGoogle Scholar
128 Hale-Donze H, Greenwell-Wild T, Mizel D et al. Mycobacterium avium complex promotes recruitment of monocyte hosts for HIV-1 and bacteria. J. Immunol.169(7),3854–3862 (2002).
Medline CASGoogle Scholar
129 Cotter R, Williams C, Ryan L et al. Fractalkine (CX3CL1) and brain inflammation: Implications for HIV-1-associated dementia. J. Neurovirol.8(6),585–598 (2002).
Medline CASGoogle Scholar
130 Garcia LS. Classification of human parasites. Clin. Infect. Dis.25(1),21–23 (1997).
Medline CASGoogle Scholar
131 Raes G, Beschin A, Ghassabeh GH, De Baetselier P. Alternatively activated macrophages in protozoan infections. Curr. Opin Immunol.19(4),454–459 (2007).
Medline CASGoogle Scholar
132 Denkers EY, Butcher BA. Sabotage and exploitation in macrophages parasitized by intracellular protozoans. Trends Parasitol.21(1),35–41 (2005).
Medline CASGoogle Scholar
133 Holscher C, Arendse B, Schwegmann A, Myburgh E, Brombacher F. Impairment of alternative macrophage activation delays cutaneous leishmaniasis in nonhealing BALB/c mice. J. Immunol.176(2),1115–1121 (2006).
MedlineGoogle Scholar
134 Iniesta V, Gomez-Nieto LC, Corraliza I. The inhibition of arginase by N(omega)-hydroxy-l-arginine controls the growth of Leishmania inside macrophages. J. Exp. Med.193(6),777–784 (2001).
Medline CASGoogle Scholar
135 Kreider T, Anthony RM, Urban JF Jr, Gause WC. Alternatively activated macrophages in helminth infections. Curr. Opin Immunol.19(4),448–453 (2007).
Medline CASGoogle Scholar
136 Porta C, Rimoldi M, Raes G et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor κB. Proc. Natl Acad. Sci. USA106(35),14978–14983 (2009).
Medline CASGoogle Scholar
137 Pesce JT, Ramalingam TR, Mentink-Kane MM et al. Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog.5(4),e1000371 (2009).
MedlineGoogle Scholar
138 Lee CG. Chitin, chitinases and chitinase-like proteins in allergic inflammation and tissue remodeling. Yonsei Med. J.50(1),22–30 (2009).
Medline CASGoogle Scholar
139 Anthony RM, Rutitzky LI, Urban JF Jr, Stadecker MJ, Gause WC. Protective immune mechanisms in helminth infection. Nat. Rev. Immunol.7(12),975–987 (2007).
Medline CASGoogle Scholar
140 Weng M, Huntley D, Huang IF et al. Alternatively activated macrophages in intestinal helminth infection: effects on concurrent bacterial colitis. J. Immunol.179(7),4721–4731 (2007).
Medline CASGoogle Scholar
141 Teixeira MJ, Teixeira CR, Andrade BB, Barral-Netto M, Barral A. Chemokines in host-parasite interactions in leishmaniasis. Trends Parasitol.22(1),32–40 (2006).
Medline CASGoogle Scholar
142 Van Zandbergen G, Klinger M, Mueller A et al. Cutting edge: neutrophil granulocyte serves as a vector for Leishmania entry into macrophages. J. Immunol.173(11),6521–6525 (2004).
Medline CASGoogle Scholar
143 Ritter U, Moll H. Monocyte chemotactic protein-1 stimulates the killing of Leishmania major by human monocytes, acts synergistically with IFN-γ and is antagonized by IL-4. Eur. J. Immunol.30(11),3111–3120 (2000).
Medline CASGoogle Scholar
144 Robben PM, LaRegina M, Kuziel WA, Sibley LD. Recruitment of Gr-1⁺ monocytes is essential for control of acute toxoplasmosis. J. Exp. Med.201(11),1761–1769 (2005).
Medline CASGoogle Scholar
145 Pearce EJ, MacDonald AS. The immunobiology of schistosomiasis. Nat. Rev. Immunol.2(7),499–511 (2002).
Medline CASGoogle Scholar
146 Lukacs NW, Kunkel SL, Strieter RM, Warmington K, Chensue SW. The role of macrophage inflammatory protein 1 α in Schistosoma mansoni egg-induced granulomatous inflammation. J. Exp. Med.177(6),1551–1559 (1993).
Medline CASGoogle Scholar
147 Smith P, Fallon RE, Mangan NE et al. Schistosoma mansoni secretes a chemokine binding protein with anti-inflammatory activity. J. Exp. Med.202(10),1319–1325 (2005).
Medline CASGoogle Scholar
148 Loberg RD, Ying C, Craig M et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res.67(19),9417–9424 (2007).▪ These preclinical studies [148–152] demonstrate that CCL2 inhibitory approaches are able to reduce macrophages infiltration and tumor growth in different models of cancers.
Medline CASGoogle Scholar
149 Mizutani K, Sud S, McGregor NA et al. The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia11(11),1235–1242 (2009).▪ These preclinical studies [148–152] demonstrate that CCL2 inhibitory approaches are able to reduce macrophages infiltration and tumor growth in different models of cancers.
Medline CASGoogle Scholar
150 Fujimoto H, Sangai T, Ishii G et al. Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int. J. Cancer125(6),1276–1284 (2009).▪ These preclinical studies [148–152] demonstrate that CCL2 inhibitory approaches are able to reduce macrophages infiltration and tumor growth in different models of cancers.
Medline CASGoogle Scholar
151 Lu X, Kang Y. Chemokine (C-C motif) ligand 2 engages CCR2⁺ stromal cells of monocytic origin to promote breast cancer metastasis to lung and Bone. J. Biol. Chem.284(42),29087–29096 (2009).▪ These preclinical studies [148–152] demonstrate that CCL2 inhibitory approaches are able to reduce macrophages infiltration and tumor growth in different models of cancers.
Medline CASGoogle Scholar
152 Popivanova BK, Kostadinova FI, Furuichi K et al. Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res.69(19),7884–7892 (2009).▪ These preclinical studies [148–152] demonstrate that CCL2 inhibitory approaches are able to reduce macrophages infiltration and tumor growth in different models of cancers.
Medline CASGoogle Scholar
153 Zhang J, Patel L, Pienta KJ. Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog. Mol. Biol. Transl Sci.95,31–53 (2010).
Medline CASGoogle Scholar
154 Struthers M, Pasternak A. CCR2 antagonists. Curr Top. Med. Chem.10(13),1278–1298 (2010).
Medline CASGoogle Scholar
155 Mantovani A. The chemokine system: redundancy for robust outputs. Immunol. Today20(6),254–257 (1999).
Medline CASGoogle Scholar
156 Kuritzkes DR. HIV-1 entry inhibitors: an overview. Curr. Opin HIV AIDS4(2),82–87 (2009).
MedlineGoogle Scholar
157 Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med.185(4),621–8 (1997).
Medline CASGoogle Scholar
158 Steen A, Schwartz TW, Rosenkilde MM. Targeting CXCR4 in HIV cell-entry inhibition. Mini Rev Med Chem (2010) (Epub ahead of print).
Google Scholar
159 Schioppa T, Uranchimeg B, Saccani A et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J. Exp. Med.198(9),1391–402 (2003).
Medline CASGoogle Scholar
160 Kryczek I, Wei S, Keller E, Liu R, Zou W. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am. J. Physiol. Cell Physiol.292(3),C987–C995 (2007).
Medline CASGoogle Scholar
161 Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest.120(3),694–705 (2010).▪▪ These studies [161–163] show that macrophages are crucial promoters of tumor relapse and suggest different strategies to inhibit macrophages recruitment in postirradiated neoplastic tissues.
Medline CASGoogle Scholar
162 Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res.70(14),5679–5685 (2010).▪▪ These studies [161–163] show that macrophages are crucial promoters of tumor relapse and suggest different strategies to inhibit macrophages recruitment in postirradiated neoplastic tissues.
Medline CASGoogle Scholar
163 Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A, Brown JM. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc. Natl Acad. Sci. USA107(18),8363–8368 (2010).▪▪ These studies [161–163] show that macrophages are crucial promoters of tumor relapse and suggest different strategies to inhibit macrophages recruitment in postirradiated neoplastic tissues.
Medline CASGoogle Scholar
164 Allavena P, Signorelli M, Chieppa M et al. Anti-inflammatory properties of the novel antitumor agent Yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res.65(7),2964–2971 (2005).
Medline CASGoogle Scholar
165 Sessa C, De Braud F, Perotti A et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J. Clin. Oncol.23(9),1867–1874 (2005).
Medline CASGoogle Scholar
166 Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol.86(5),1065–1073 (2009).
Medline CASGoogle Scholar
167 D’Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol. Cancer Ther.9(8),2157–2163 (2010).
MedlineGoogle Scholar
168 Germano G, Frapolli R, Simone M et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res.70(6),2235–2244 (2010).
Medline CASGoogle Scholar
169 Carter NJ, Keam SJ. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. Drugs70(3),355–376 (2010).
Medline CASGoogle Scholar
170 Rogers MJ, Crockett JC, Coxon FP, Monkkonen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone49(1),34–41 (2011).
Medline CASGoogle Scholar
171 Coleman RE, McCloskey EV. Bisphosphonates in oncology. Bone49(1),71–76 (2011).
Medline CASGoogle Scholar
172 Clezardin P, Benzaid I, Croucher PI. Bisphosphonates in preclinical bone oncology. Bone49(1),66–70 (2011).
Medline CASGoogle Scholar
173 Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med.360(7),679–691 (2009).
Medline CASGoogle Scholar
174 Morgan G, Lipton A. Antitumor effects and anticancer applications of bisphosphonates. Semin. Oncol.37(Suppl. 2),S30–S40 (2010).
Medline CASGoogle Scholar
175 Zarogoulidis K, Boutsikou E, Zarogoulidis P et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int. J. Cancer125(7),1705–1709 (2009).
Medline CASGoogle Scholar
176 Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer100(12),2613–2621 (2004).
Medline CASGoogle Scholar
177 Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int. J. Clin. Oncol.15(4),382–389 (2010).
Medline CASGoogle Scholar
178 Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst.96(11),879–882 (2004).
Medline CASGoogle Scholar
179 Owais M, Gupta CM. Targeted drug delivery to macrophages in parasitic infections. Curr. Drug Deliv.2(4),311–318 (2005).
Medline CASGoogle Scholar
180 Gazzaniga S, Bravo AI, Guglielmotti A et al. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J. Invest. Dermatol.127(8),2031–2041 (2007).
Medline CASGoogle Scholar
181 Kelly C, Jefferies C, Cryan SA. Targeted liposomal drug delivery to monocytes and macrophages. J. Drug Deliv. 2011:727241 (2011).
MedlineGoogle Scholar
182 Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: role of physicochemical properties of particulate carriers – liposomes and microspheres – on the phagocytosis by macrophages. J. Control. Release79(1–3),29–40 (2002).
Medline CASGoogle Scholar
183 Foged C, Arigita C, Sundblad A, Jiskoot W, Storm G, Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine22(15–16),1903–1913 (2004).
Medline CASGoogle Scholar
184 Irache JM, Salman HH, Gamazo C, Espuelas S. Mannose-targeted systems for the delivery of therapeutics. Expert Opin Drug Deliv.5(6),703–724 (2008).
Medline CASGoogle Scholar
185 De Palma M, Mazzieri R, Politi LS et al. Tumor-targeted interferon-α delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell14(4),299–311 (2008).
Medline CASGoogle Scholar
186 De Palma M, Naldini L. Tie2-expressing monocytes (TEMs): novel targets and vehicles of anticancer therapy? Biochem. Biophys. Acta1796(1),5–10 (2009).
Medline CASGoogle Scholar
187 Antonelli LR, Gigliotti Rothfuchs A, Goncalves R et al. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J. Clin. Invest.120(5),1674–1682 (2010).
Medline CASGoogle Scholar
188 Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res.65(8),3437–3446 (2005).
Medline CASGoogle Scholar
189 Coscia M, Quaglino E, Iezzi M et al. Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J. Cell Mol. Med.14(12),2803–2815 (2009).
Google Scholar
190 Duluc D, Corvaisier M, Blanchard S et al. Interferon-γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int. J. Cancer125(2),367–373 (2009).
Medline CASGoogle Scholar
191 Ostrand-Rosenberg S, Grusby MJ, Clements VK. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J. Immunol.165(11),6015–6019 (2000).
Medline CASGoogle Scholar
192 Kortylewski M, Kujawski M, Wang T et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med.11(12),1314–1321 (2005).
Medline CASGoogle Scholar
193 Hagemann T, Biswas SK, Lawrence T, Sica A, Lewis CE. Regulation of macrophage function in tumors: the multifaceted role of NF-κB. Blood113(14),3139–3146 (2009).
Medline CASGoogle Scholar
194 Beatty GL, Chiorean EG, Fishman MP et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science331(6024),1612–1616 (2011).▪▪ Remarkable study that demonstrates that CD40 agonists induce M1 macrophage activation and pancreatic tumors inhibition in both mice and humans.
Medline CASGoogle Scholar
195 Weiss JM, Back TC, Scarzello AJ et al. Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc. Natl Acad. Sci. USA106(46),19455–60 (2009).
Medline CASGoogle Scholar
196 Weiss JM, Ridnour LA, Back T et al. Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J. Exp. Med.207(11),2455–67 (2010).
Medline CASGoogle Scholar

Vol. 3, No. 10

Metrics

Downloaded 333 times

History

Published online 13 October 2011

Published in print October 2011

Information

Keywords

Financial & competing interests disclosure

This work was supported by Associazione Italiana Ricerca sul Cancro (AIRC), Italy; Fondazione Cariplo, Italy; Ministero Università Ricerca (MUR), Italy; Ministero della Salute and Regione Piemonte (project number 331, august 8th, 2009). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download

Macrophages in cancer and infectious diseases: the ‘good’ and the ‘bad’

Abstract

Bibliography